Statistical collaboration to impact policy decisions

Statistics in Medicine

Volumn 24, Issue 4, 2005, Pages 493-501

  Morton, Sally C ^a  

^a RAND CORPORATION   (United States)

Author keywords

Collaboration; Consulting; Health services research

Indexed keywords

EPHEDRINE;

BODY WEIGHT DISORDER; CLINICAL TRIAL; CONFIDENCE INTERVAL; COOPERATION; COST OF ILLNESS; DATA ANALYSIS; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH PROMOTION; HEALTH STATISTICS; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; MORTALITY; OUTCOMES RESEARCH; REVIEW; STATISTICAL ANALYSIS; STATISTICAL MODEL; SYSTEMATIC REVIEW; UNITED STATES;

COOPERATIVE BEHAVIOR; EPHEDRA; HEALTH POLICY; HEALTH SERVICES; HEALTH SERVICES RESEARCH; HIV INFECTIONS; HUMANS; POLICY MAKING; RESEARCH DESIGN; STATISTICS; UNITED STATES;

EID: 13844255396     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.2075     Document Type: Review

References (13)

1. Merriam-Webster Inc. Webster's Ninth New Collegiate Dictionary. Merriam-Webster Inc: Springfield, MA, 1986.
2. Dutch RA (ed.). The Original Roget's Thesaurus of English Words and Phrases. St. Martin's Press: New York, NY, 1965.
3. O'Fallon JR. Comments on biostatistical collaboration in medical research. Biometrics 1990; 46:24-26.
4. Shapiro MF, Berk ML, Berry SH et al. National probability samples in studies of low-prevalence diseases. Part I: perspectives and lessons from the HIV cost and services utilization study. Health Service Research 1999; 34(5 Part 1):951-968.
5. Frankel MR, Shapiro MF, Duan N et al. National probability samples in studies of low-prevalence diseases. Part II: Designing and implementing the HIV cost and services utilization study sample. Health Service Research 1999; 34(5 Part 1):969-992.
6. Bozzette SA, Berry SH, Duan N et al. The care of HIV-infected adults in the United States. HIV cost and services utilization study consortium. New England Journal of Medicine 1998; 339(26):1897-1904.
7. Goldman DP, Bhattacharya J, McCaffrey DF et al. Effect of insurance on mortality in an HIV-positive population in care. Journal of the American Statistical Association 2001; 96 455):883-894.
8. Shapiro MF, Morton SC, McCaffrey DF et al. Variations in the care of HIV-infected adults in the United States: results from the HIV cost and services utilization study. JAMA 1999; 281 24):2305-2315.
9. Redfearn S. Ephedra products thin out. The Washington Post January 14, 2003 (Health, HE01).
10. Shekelle PG, Morton SC, Maglione M (Southern California - RAND Evidence-Based Practice Center). Ephedra and ephedrine for weight loss and athletic performance enhancement: clinical efficacy and side effect. Evidence Report/Technology Assessment No. 76. Agency for Healthcare Research and Quality; Rockville, MD, 2003 (Publication No. 03-E022, Contract No.: 290-97-0001).
11. Shekelle PG, Hardy ML, Morton SC et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289(12):1537-1545.
12. U.S. Food and Drug Administration (FDA). FDA fact sheet. HHS acts to reduce safety concerns associated with dietary supplements containing ephedra, February 28, 2003 [press release]. Available at: http://www.fda.gov/bbs/topics/NEWS/ephedra/factsheet.html
13. U.S. Food and Drug Administration (FDA). FDA fact sheet. FDA announces plans to prohibit sales of dietary supplements containing ephedra, December 30, 2003 [press release]. Available at: http://www.fda.gov/oc/initiatives/ephedra/december2003/